David Wallach
LIST OF PUBLICATIONS
Experimental Papers
1. Wallach, D., and Schramm, M. (1971): Calcium and exportable protein in rat parotid gland, parallel
subcellular distribution and concomitant secretion. Eur. J. Biochem. 21, 443-437.
2. Wallach, D., Bar-Nun, S., and Ohad, I. (1972): Biogenesis of chloroplast membranes. IX. Development
of photophosphorylation and proton pump activities in greening Chlamydomonas reinhardi y-1 measured
with open-cell preparation. Biochim. Biophys. Acta 267, 125-137.
3. Bar-Nun, S., Wallach, D., and Ohad, I. (1972): Biogenesis of chloroplast membranes. X. Changes in the
photosynthetic specific activity and the relationship between the light harvesting system and
photosynthetic electron transfer chain during greening of Chlamydomonas reinhardi y-1 cells. Biochim.
Biophys. Acta 267,138-148.
4. Kirshner, N., Wallach, D., Sharoni, Y. and Schramm, M. (1973): Purification of secretory granules on a
urografin gradient. Anal. Biochem. 52, 589-594.
5. Wallach, D., Kirshner, N. and Schramm, M. (1975): Non-parallel transport of membrane proteins and
content proteins during assembly of the secretory granule in rat parotid gland. Biochim. Biophys. Acta
375, 87-105.
6. Wallach, D., Tessler, R., and Schramm, M. (1975): The proteins of the content of the secretory granules
of the rat parotid gland. Biochim. Biophys. Acta 382, 552-564.
7. Wallach, D. and Pastan, I. (1976): Stimulation of guanylate cyclase of fibroblasts by free fatty acids. J.
Biol. Chem. 251, 5802-5809.
8. Wallach, D. and Pastan, I. (1976): Stimulation of membranous guanylate cyclase by concentrations of
calcium that are in the physiological range. Biochem. Biophys. Res. Comm. 72, 859-865.
9. Wallach, D., Anderson, W. and Pastan, I. (1978): Activation of adenylate cyclase in cultured fibroblasts
by trypsin. J. Biol. Chem. 253, 24-26.
10.Wallach, D., Davies, P.J.A. and Pastan, I. (1978): Purification of mammalian filamin, similarity to high
molecular weight actin binding protein in macrophages, platelets, fibroblasts and other tissues. J. Biol.
Chem. 253, 3328-3335.
11.Davies, P.J.A., Wallach, D., Willingham, M.C. Pastan, I., Yamaguchi, M. and Robson, R.M. (1978):
Filamin actin interaction; dissociation of binding from gelation by Ca2+ activated proteolysis. J. Biol.
Chem. 253, 4036-4042.
12.Wallach, D., Davies, P. and Pastan, I. (1978): Cyclic AMP dependent phosphorylation of filamin in
mammalian smooth muscle. J. Biol. Chem. 253, 4739-4745.
13.Wallach, D. and Revel, M. (1979): Hormonal protection of interferon-treated cells against doublestranded RNA induced cytolysis. FEBS Letters 101, 364-368.
14.Wallach, D. and Revel, M. (1980): An interferon-induced cellular enzyme is incorporated into virions.
Nature 287, 68-70.
15.Weissenbach, J., Chernajovsky, Y., Zeevi, M., Shulman, L., Soreq, H., Nir, U., Wallach, D., Ferricaudet,
M., Tiollais, P. and Revel, M. (1980): Two interferon mRNAs in human fibroblast in vitro translation
and E. coli cloning studies. Proc. Natl. Acad. Sci. USA 77, 7152-7156.
16.Davies, P.J.A., Wallach, D., Willingham, M., Pastan, I. and Lewis, M.S. (1980): Self-association of
chicken gizzard filamin and heavy merofilamin. Biochemistry 19, 1366-1372.
17.Merlin, G., Revel, M. and Wallach, D. (1981): The interferon-induced enzyme oligo-isoadenylate
synthetase. Rapid determination of its in vitro products. Analytical Biochemistry 110, 190-196.
18.Schattner, A., Merlin, G., Levin, S., Wallach, D., Hahn, T. and Revel, M. (1981): Assay of an interferoninduced enzyme in white blood cells as a diagnostic aid in viral diseases. The Lancet 2, 497-500.
19.Schattner, A., Merlin, G., Wallach, D., Rosenberg, H., Bino, T., Hahn, T., Levin, S. and Revel M. (1981):
Monitoring of interferon therapy by assay of (2'-5') oligo-iso-adenylate synthetase in human peripheral
white blood cells. Journal of Interferon Research 1, 587-593.
20.Fellous, M., Nir, U., Merlin, G., Rubinstein, M., Wallach, D. and Revel, M. (1982): Interferon-dependent
induction of mRNA for the major histocompatibility antigens in human fibroblast and lymphoblastoid
cells. Proc. Natl. Acad. Sci. USA 79, 3082-3086.
21.Wallach, D. (1982): Regulation of susceptibility to natural killer cells cytotoxicity and regulation of HLA
synthesis: Differing efficacies of Alpha, Beta and Gamma interferons. Journal of Interferon Research 2,
329-338.
22.Schattner, A., Wallach, D., Merlin, G., Hahn, T., Levin, S., Ramot, B. and Revel, M. (1982): Variation of
(2'-5') oligo A synthetase level in lymphocytes and granulocytes of patients with viral infections and
leukemia. Journal of Interferon Research 2, 355-361.
23.Schattner, A., Merlin, G., Shapira, A., Revel, M. and Wallach, D. (1982): Comparison of (2'-5') oligoadenylate synthetase and interferon blood levels in mice early after viral infection. Journal of Interferon
Research 2, 285-289.
24.Schattner, A., Meshorer, A., Revel, M. and Wallach, D. (1982): Interferon as a possible cause for virus
related lymphopenia. Israel J. of Medical Sciences 18, 965-966.
25.Zor, U., Ben-Dori, R., Maoz, I., Wallach, D. and Gurari-Rotman, D. (1982): Inhibition by
glucocorticosteroid hormones of interferon and prostaglandin E induction by poly (rI):(rC). J. Gen.
Virology 63, 359-363.
26.Wallach, D., Fellous, M. and Revel, M. (1982): Preferential effect of immune interferon- on the
synthesis of HLA antigens and their mRNAs in human cells. Nature 299, 833-836.
27.Wallach, D. (1983): Interferon-induced resistance to the killing by NK cells: A preferential effect of IFNg. Cell Immunol. 75, 390-395.
28.Wallach, D. and Hahn, T. (1983): Enhanced release of lymphotoxins by interferon-treated cells. Cell
Immunol. 76, 390-396.
29.Schattner, A., Meshorer, A. and Wallach, D. (1983):
lymphopenia. Cell Immunol. 79, 11-25.
Involvement of interferon in virus-induced
30.Gazitt, Y., Ben Bassat, H., Wallach, D., Revel, M. and Schattner, A. (1983): Interferon induced
cytotoxicity and (2'-5') oligo A synthetase activity in T cells. Differences in responsiveness among T
cells from various individuals and among lymphoblastoid T cell lines. Clin. Immunol. and
Immunopathol. 30, 71-79.
31.Wallach, D. (1983): Quantification of the antiviral effect of interferon by immuno-assay of VSV proteins.
J. Gen. Virol. 64, 2221-2227.
32.Rosa, F., Hatat, D., Abadie, A., Wallach, D., Revel, M. and Fellous, M. (1983): Differential regulation of
HLA-DR mRNAs and cell surface antigens by interferon. EMBO J. 9, 1585-1589.
33.Wallach, D. (1983): The HLA proteins and a related protein of 28kDa are preferentially induced by
interferon- in human WISH cells. Eur. J. Immunol. 13, 794-798.
34.Shoham, J., Cohen, M. and Wallach, D. (1984): An immunoenzymatic quantitative assay for the antiviral
effect of interferons. J. Immunol. Meth. 72, 279-287.
35.Wallach, D. (1984): Preparations of lymphotoxin induce resistance to their own cytotoxic effect. J.
Immunol. 132, 2464-2469.
36.Schattner, A., Merlin, G., Bregman, V., Hahn, T., Levin, S., Revel, M. and Wallach, D. (1984): (2'-5')
oligo A synthetase in huma polymorphonuclear cells. Increased activity in interferon treatment and in
viral infections. Clin. Exp. Immunol. 57, 265-270.
37.Wallach, D., Hahn, T. and Budilovsky, S. (1984): Translation of mRNA for human lymphotoxin in
microinjected Xenopus oocytes. FEBS Letts. 178, 257-263.
38.Schonfeld, A., Schattner, A., Crespi, M., Levavi, H., Shoham, J., Nitke, S., Wallach, D., Hahn, T.,
Yarden, O., Doerner, T. and Revel, M. (1984): Intramuscular human interferon-b injections in treatment
of condylomata acuminata. The Lancet 1038-1042.
39.Aderka, D., Novick, D., Hahn, T., Fischer, D.G. and Wallach, D. (1985): Increase of vulnerability to
lymphotoxin in cells infected by VSV and its further augmentation by IFN. Cell Immunol. 92, 218-225.
40.Hahn, T., Toker, L., Budilovsky, S., Aderka, D., Eshhar, Z. and Wallach, D. (1985): Use of monoclonal
antibodies to a human cytotoxin for its isolation and for examining the self-induction of resistance to this
protein. Proc. Natl. Acad. Sci. USA 82, 3814-3818.
41.Aderka, D., Levo, Y., Rahmani, R., Mory, Y., Vaks, B., Horovitz, O., Doerner, T., Shoham, J., Wallach,
D. and Revel, M. (1985): Rapid improvement in a terminal case of Hairy cell leukemia treated with a
new human recombinant interferon, IFN-C. Israel J. Med. Sci. 21, 977-981.
42.Aderka, D., Fischer, S., Levo, Y., Holtman, H., Hahn, T. and Wallach, D. (1985): Cachectin/tumor
necrosis factor production by cancer patients. The Lancet 2, 1190.
43.Aderka, D., Hahn, T. and Wallach, D. (1985): Involvement of cytotoxins in the immune response to viral
infection. Antiviral Res. Suppl. 1, 141-148.
44.Israel, S., Hahn, T., Holtmann, H. and Wallach, D. (1986): Binding of human TNF- to high affinity cell
surface receptors: effect of IFN. Immunology Lett. 12, 217-224.
45.Aderka, D., Holtmann, H., Toker, L., Hahn, T. and Wallach, D. (1986): Tumor necrosis factor induction
by Sendai virus. J. Immunol. 136, 2838-2942.
46.Holtmann, H. and Wallach D. (1987): Down regulation of the receptors for tumor-necrosis-factor by
interleukin 1 and 4-Phorbol-12-myristate-13-acetate. J. Immunol. 139, 1161-1167.
47.Aderka, D., Levo, Y., Ramot, B., Michalewicz, R., Meytes, D., Shaklai, M., Hahn, T., Holtmann, H.,
Revel, M. and Wallach, D. (1987): Reduced production of tumor necrosis factor (TNF) by mononuclear
cells in hairy cell leukemia patients and improvement following interferon therapy. Cancer 60, 22082212.
48.Holtmann, N., Hahn, T. and Wallach, D. (1988): Interrelated effects of tumor necrosis factor and
interleukin-1 on cell viability. Immunobiology 177, 7-22.
49.Wallach, D., Holtmann, H., Engelmann, H. and Nophar, Y. (1988): Sensitization and desensitization to
lethal effects of tumor necrosis factor and interleukin-1. J. Immunol. 140, 2994-2999.
50.Nophar, Y., Holtmann, H., Ber, R. and Wallach, D. (1988): Dominance of resistance to the cytocidal
effect of tumor necrosis factor in heterokaryons formed by fusion of resistant and sensitive cells. J.
Immunol. 140, 3456-3460.
51.Korn, J.H., Mory, Y., Zilberstein, A., Holtmann, H., Revel, M. and Wallach, D. (1988): Cloning of
genomic DNA for tumor necrosis factor and efficient expression in CHO cells. Lymphokine Res. 7, 349358.
52.Ophir, D., Hahn, T., Schattner, A., Wallach, D. and Aviel, A. (1988): Tumor necrosis factor in middle
ear effusions. Arch. Otolaryngol. Head Neck Surg. 114, 1256-1258.
53.Shemer-Avni, Y., Wallach, D. and Sarov, I. (1988): Inhibition of Chlamydia trachomatis growth by
recombinant tumor necrosis factor. Infect. Immun. 56, 2503-2506.
54. Aderka, D., Michalevicz, R., Daniel, Y., Levo, Y., Douer, D., Ben-Bassat, I., Ramot, B., Shaklai, M.,
Prokocimer, M., Berrebi, A., Meytes, D., Rosenbaum, H., Wallach, D. and Revel, M. (1988):
Recombinant interferon alpha-C for advanced hairy cell leukemia. An Israeli multicenter study. Cancer
61, 2207-2213.
55.Engelmann, H., Aderka, D., Rubinstein, M., Rotman, D. and Wallach, D. (1989): A tumor necrosis factor
(TNF)-binding protein purified to homogeneity from human urine protects cells from TNF toxicity. J.
Biol. Chem. 264, 11974-11980.
56.Wallach, D., Holtmann, H., Aderka, D., Rubinstein, M., Shemer-Avni, Y., Sarov, I. and Engelmann, H.
(1989): Mechanisms which take part in regulation of the response to tumor necrosis factor. Lymphokine
Res. 8, 359-363.
57.Shemer-Avni, Y., Wallach, D. and Sarov, I. (1989): Reversion of the anti-chlamydial effect of tumor
necrosis factor by tryptophan and antibodies to beta interferon. Infect. Immun. 57, 3484-3490.
58.Novick, D., Engelmann, H., Wallach, D. and Rubinstein, M. (1989): Soluble cytokine receptors are
present in normal urine. J. Exp. Med. 170, 1409-1414.
59.Israel, A., Le Bail, O., Piette, J., Kieran, M., Logeat, F., Wallach, D., Fellows, M. and Kourilsky, P.
(1989): TNF stimulates expression of mouse MHC class I genes by inducing a new enhancer binding
protein which displaces constitutive factors. EMBO J. 8, 3793-3800.
60.Engelmann, H., Novick, D. and Wallach, D. (1990): Two tumor necrosis factor binding proteins purified
from human urine. Evidence for immunological cross reactivity with cell surface tumor-necrosis-factor
receptors. J. Biol. Chem. 265, 1531-1536.
61.Novick, D., Engelmann, H., Wallach, D., Leitner, O., Revel, M. and Rubinstein, M. (1990): Purification
of soluble cytokine receptors from normal human urine by ligand-affinity and immunoaffinity
chromatography. J. Chromatography 510, 331-337.
62.Zolti, M., Meirom, R., Shemesh, M., Wallach, D., Meshiach, S., Shore, L. and Ben Rafael, Z. (1990):
Granulosa cells as a source and target organ for tumor necrosis factor-. FEBS Letters 261, 253-255.
63.Yuhas, Y., Holtmann, H., Shemer-Avni, Y., Sarov, I. and Wallach, D. (1990): Inhibition of tumor
necrosis factor-induced cell-killing by tryptophan and indole. Eur. Cytokine Net. 1, 35-40.
64.Engelmann, H., Holtmann, H., Brakebusch, C., Shemer-Avni, Y., Sarov, I., Nophar, Y., Hadas, E.,
Leitner, O. and Wallach. D. (1990): Antibodies to a soluble form of a tumor necrosis factor (TNF)
receptor have TNF-like activity. J. Biol. Chem. 265, 14497-14504.
65.Holtmann, H., Shemer-Avni, Y., Wessel, K., Sarov, I. and Wallach, D. (1990): Inhibition of growth of
Chlamydia trachomatis by tumor necrosis factor is accompanied by increased prostaglandin synthesis.
Infect. Immunol. 58, 3168-3172.
66.Nophar, Y., Kemper, O., Brakebusch, C., Engelmann, H., Zwang, R., Aderka, D., Holtmann, H. and
Wallach, D. (1990): Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type
I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a
soluble form of the receptor. EMBO J. 9, 3269-3278.
67.Derré, J., Kemper, O., Cherif, D., Nophar, Y. Berger, R. and Wallach, D. (1991). The gene for the type 1
tumor necrosis factor receptor (TNF-RI) is localized on band 12p13. Human Genetics 87, 231-233.
68.Kemper, O., Derré, J. Cherif, D., Engelmann, N., Wallach, D. and Berger, R. (1991): The gene for the
type II (p75) tumor necrosis factor receptor/(TNF-RII) is localized on band 1p36.2-p.36.3. Human
Genetics 87, 623-624.
69.Koenig, M., Wallach, D., Resch, K. and Holtmann, H. (1991). Induction of hyporesponsiveness to an
early post-binding effect of tumor-necrosis-factor (TNF) by TNF and interleukin 1. Eur. J. Immunol. 21,
1741-1745.
70.Aderka, D., Engelmann, H., Hornik, V., Skornick, Y., Levo, Y., Wallach, D. and Kushtai, G. (1991):
Increased serum levels of soluble receptors for tumor necrosis factor in Cancer patients. Cancer Res. 51,
5602-5607.
71.Porteu, F., Brockhaus, M., Wallach, D., Engelmann, H. and Nathan, C-F. (1991): Human neutrophil
elastase releases a ligand-binding fragment from the 75 kDa tumor necrosis factor receptor. Comparison
with the proteolytic activity responsible for shedding of TNF receptors from stimulated neutrophils. J.
Biol. Chem. 266, 18846-18853.
72.Aderka, D., Engelmann, H., Maor, Y., Brakebush, C. and Wallach, D. (1992): Stabilization of the
Bioactivity of tumor necrosis factor (TNF) by its soluble receptors. J. Exp. Med.175, 323-329.
732.Winzen, R., Wallach, D., Engelmann, H., Nophar, Y., Brakebusch, C., Kemper, O., Resch, K. and
Holtmann, H. (1992): Selective decrease in cell surface expression and mRNA level of the 55-kDa tumor
necrosis factor receptor during differentiation of the HL-60 cells into macrophage-like but not
granulocyte-like cells. J. Immunol. 148, 3454-3460.
74.Brakebusch, C., Nophar, Y., Kemper, O., Engelmann, H. and Wallach, D. (1992): Cytoplasmic
truncation of the p55 tumor necrosis factor (TNF) receptor abolishes signalling, but not induced shedding
of the receptor. EMBO J. 11, 943-950.
75.Aderka, D., Engelmann, H., Shemer-Avni, Y., Hornik, V., Galil, A., Sarov, B. and Wallach, D. (1992):
Variation in serum levels of the soluble TNF receptors among healthy individuals. Lymphokine and
Cytokine Research 11, 157-159.
76.Cope, A.P., Aderka, D., Doherty, M., Engelmann, H., Gibbons, D., Jones, A., Brennan, M.F., Maini, R.N,
Wallach, D., and Feldmann, M. (1992): Increased levels of soluble tumour necrosis factor receptors in
the sera and synovial fluid of patients with rheumatic diseases. Arthritis and Rheumatism. 35, 1160-1169.
77.Miles, D.W., Aderka, D., Engelmann. H., Wallach, D. and Balkwill F.R. (1992): Induction of soluble
Tumor Necrosis Factor receptors during treatment with interleukin-2. Brit. J. of Cancer 66, 1195-1199.
78.Kalinkovich, A., Engelmann, H., Harpaz, N., Burstein, R., Barak, V., Kalickman, I., Wallach, D. and
Bentwich, Z. (1992): Elevated serum levels of soluble tumour necrosis factor receptors (sTNF-R) in
patients with HIV infection. Clin. exp. Immunol. 89, 351-355.
79.Gascon, M-P., Porchet, H.C., Le Cotonnec, J-Y., Ythier, A., Wallach., D, Piguet, P-F. and Grau, G.
(1992): Pharmacokinetics and tissue distribution of human urinary tumor necrosis factor binding protein
in mice. Drug Metabolism and Disposition. 20, 592-595.
80.Hershkoviz, R., Gilat, D., Miron, S., Mekori, Y. A., Aderka, D., Wallach. D., Vlodavsky, I., Cohen, I.R.
and Lider, O. (1993): Extracellular matrix induces tumor necrosis factor-a secretion by an interaction
between resting CD4+ T cells and macrophages. Immunology. 78, 50-57.
81. Aderka, D., Wysenbeek, A.J., Cope, A., Engelmann, H., Molad, Y., Hornik, V., Levo, Y., Feldmann, M.
and Wallach, D. (1993): Correlation between serum levels of soluble tumor necrosis factor receptor and
disease activity in systemic lupus erythematosus. Arthr. Rheum. 38, 1111-1120.
82. Noronha, I.L., Hartley, B., Wallach, D., Cameron, J.S. and Waldherr, R. (1993): Expression of
Cytokines, growth factors and their receptors in renal allograft biopsies. Transplantation Proc.,25, 917918.
83. Kemper, O. and Wallach, D. (1993): Cloning and partial characterization of the promoter for the human
p55 tumor necrosis factor (TNF) receptor. Gene., 134. 209-216.
84. Ythier, A. Gascon, M-P., Juillard, P., Vesin, C., Wallach, D. and Grau, G. (1993): Protective effect of
natural TNF-binding protein on human TNF-induced toxicity in mice. Cytokine. 5, 459-492.
85. Kalinkovich, A., Livshits, G., Engelmann, H., Harpaz, N., Burstein., R, Kaminsky, M., Wallach, D. and
Bentwich Z. (1993): Soluble tumour necrosis factor receptors (sTNF-R) and HIV infection: correlation
to CD8+ lymphocytes. Clin Exp Immunol. 93, 350-355.
86.Winzen, R., Wallach, D., Kemper, O., Resch, K. and Holtmann, H. (1993): Selective up-regulation of the
75-kDa tumor necrosis factor (TNF) receptor and its mRNA by TNF and IL-1. J Immunol., 150, 43464353.
87. Aderka, D., Maor, Y., Novick, D., Engelmann, H., Kahn., Y; Levo, Y., Wallach, D. and Revel, M.
(1993): Interleukin-6 inhibits the proliferation of B-chronic lymphocytic leukemia cells that is induced
by tumor necrosis factor-alpha or -beta. Blood., 81, 2076-2084.
88. Belldegrun, A., Pierce, W., Sayah, D., de, Kernion, J., Wallach, D., Aderka, D. and Figlin, R. A. (1993):
Soluble tumor necrosis factor receptor expression in patients with metastatic renal cell carcinoma treated
with interleukin-2-based immunotherapy. J Immunother., 13, 175-180.
89.Cope, A, P., Gibbons, D, L., Aderka, D., Foxwell, B. M., Wallach, D., Maini, R, N. Feldmann, M., and
Brennan, F, M. (1993): Differential regulation of tumor necrosis factor receptors (TNF-R) by IL-4;
upregulation of p55 and p75 TNF-R on synovial mononuclear cells., Cytokine. 5, 205-212.
90.Molyneux, M. E., Engelmann, H., Taylor, T. E., Wirima, J. J., Aderka, D., Wallach, D. and Grau, G. E.
(1993): Circulating plasma receptors for tumor necrosis factor in malawian children with severe
falciparum malaria., Cytokine, 6, 604-609.
91.Alon, R., Cahalon, L., Hershkovitz, R., Elbaz, D., Reizis, B., Wallach, D., Akiyama, S. K., Yamada, K.
and Lider, O. (1994): TNF- binds to the N-terminal domain of fibronectin and augments the 1Integrin-mediated adhesion of CD4+ T lymphocytes to the glycoprotein., J. Immunol., 152, 1304-1313.
92.Ettehadi. P., Greaves, M. W., Wallach, D., Aderka, D., and Camp, R. D., R. (1994): Elevated tumor
necrosis factor alpha (TNF-) biological activity in psoriatic skin lesions., Clin. Exp. Immunol., 96, 146151.
93.Bigda, J., Beletsky, I., Brakebusch, C., Varfolomeev, Y., Engelmann, H., Bigda, J., Holtmann, H. and
Wallach D., (1994): Dual role of the p75 tumor necrosis factor (TNF) receptor in the induction of TNF
cytotoxicity., J. Exp. Med., 180, 445-460.
94.Kuhnert, P., Kemper, O. and Wallach., (1994):
Cloning, sequencing and partial functional
characterization of the 5' region of the human p75 tumor necrosis factor (TNF) receptor gene, Gene,
150, 381-386.
95.Boka, G., Anglade, P., Wallach, D., Javoy-Agid, F., Agid, Y. and Hirsch, E. C., (1994):
Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease.,
Neuroscience Letters, 172, 161-154.
96. Brakebusch, C., Varfolomeev, Y., Batkin, M. and Wallach, D. (1994) Structural requirements for
inducible shedding of the p55 tumor necrosis factor (TNF) receptor. J. Biol. Chem. 269, 32488-32496 .
97.Boldin, M. P., Mett, I. L., Varfolomeev, E. E., Chumakov, I., Shemer-Avni, Y., Camonis, J. H., and
Wallach, D. (1995) Self-association of the 'death domains' of the p55 tumor necrosis factor (TNF)
receptor and Fas/APO1 prompts signaling for TNF and Fas/APO1 effects. J. Biol. Chem., 270, 387-391.
98. Cope, A. P., Aderka, D., Wallach, D., Kahan, M., Chu, N. R. and Brennan, F. M. (1995) Soluble TNF
receptor production by activated T lymphocytes: differential effects of acute and chronic exposure to
TNF. Immunology, 84, 21-30.
99. Boldin, M. P., Varfolomeev, E. E., Pancer, Z., Mett, I. L., Camonis, J. H., and Wallach, D. (1995) A
novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the
death domain. J. Biol. Chem., 270, 7795-7798.
100. Porat, R., Paddock,H. N., Schwaitzberg, S. D., Connolly, R. J., Wilkens, T., Dasch, J. R., Gascon, M.
P., Hutchison, J. S., Ythier, A., Wallach, D., et al (1995) Glycosylated recombinant human tumor
necrosis factor binding protein-1 reduces mortality, shock, and production of tumor necrosis factor in
rabbit Escherichia coli sepsis. Crit Care Med., 23, 1080-1089.
101. Kalinkovich, A., Geleziunas, R., Kemper, O., Belenki, D., Wallach, D., Wainberg, M. A. and
Bentwitch, Z. (1995) Increased soluble tumor necrosis factor receptor expression and release by human
immunodefficiency virus type 1 infection. J. Interferon. Cytokines Res., 9, 749-757
102. Sissel-Linda, O., Novick, D., Wathen, N. C., Cope, A. P., Wallach, D. and Aderka, D. (1995) Soluble
tumor necrosis factor receptors and soluble interleukin-6 receptor in fetal and and maternal sera, coelomic
and amniotic fluids in normal and pre-eclamptic pregnancies. J. Reproductive Immunology, 29, 119-134.
103.Boldin, M. P., Mett, I. L., and Wallach, D. (1995) A protein related to a proteasomal subunit binds to the
intracellular domain of the p55 TNF receptor upstream to its 'death domain'. FEBS Letters, 367, 39-44.
104. Pócsik, É., Duda, E., and Wallach, D. (1995) Phosphorylation of the 26 kDa TNF precursor in
monocytic cells and in transfected HeLa cells. J. Inflammation, 45, 152-160.
105. Varfolomeev, E. E., Boldin, M. P., Goncharov T. M., and Wallach D. (1996) A potential mechanism of
"cross-talk" between the p55 TNF receptor and Fas/APO1: Proteins binding to the death domains of the
two receptors bind also to each other. J. Exp. Med., 183, 1271-1276.
106. Sarov I., Geron, E., Shemer-Avni Y., Manor, E., Zvillich, M., Wallach, D., Schmitz, E and Holtmann,
H. (1990) Implications for persistent chlamydial infections of phagocyte-microorganism interplay. Eur J
Clin Microbiol Infect Dis, 10, 119-123.
107. Sippy, D. B., Hofman, M. F., Wallach, D. and Hinton, R. D., (1995) Increased expression of tumor
necrosis factor- receptors in the brains of patients with AIDS. Journal of Acquired Immune Deficiency
Syndromes and Human Retrovirology, 10, 511-521.
108. Eliaz, R., Wallach, D. and Kost J. (1996) Long-term protection against tumor necrosis factor (TNF)
effects by controlled delivery of the soluble p55 tumor necrosis factor receptor, Cytokine, 8, 482-487.
109. Boldin, M. P., Goncharov, T. M., Goltsev, Y. V. and Wallach, D. (1996) Involvement of MACH, a
novel MORT1/FADD-interacting protease, in Fas/APO1- and TNF receptor-induced cell death, Cell, 85,
803- 815.
110. Tur-Kaspa, I., Maor, Y., Weissenberg, R., Madgar, I., Aderka, D., Dor, J., Mashiach, S. and Wallach,
David., (1996) High levels of soluble p55-TNF receptors in seminal and prostatic fluids of normal and
infertile men. The Journal of Urology, 155, 1436-1438.
111. Malinin, N. L., Boldin, M. P., Kovalenko, A. V. and Wallach, D. (1997) MAP3K-related kinase
involved in NF-B induction by TNF, CD95 and IL-1. Nature, 385, 540-544.
112. Goltsev, Y. V., Kovalenko, A. V., Arnold, E., Varfolomeev, E. E., Brodianskii, V. M. and Wallach
D.(1997). CASH, a novel caspase homologue with death effector domains. J. Biol. Chem. 272, 1964119644.
113. Aderka, D., Sorkine P., Abu-Abid, S., Lev, D., Setton, A., Cope, A. P., Wallach, D. and Klausner, J.
(1998). Shedding kinetics of soluble tumor necrosis factor (TNF) receptors after systemic TNF leaking
during isolated limb perfusion. Relevance to the pathophysiology of septic shock J. Clin. Invest. 101,
650-659.
114. Varfolomeev, E. E., Schuchmann, M., Luria, V., Chiannilkulchai, N., Beckmann, J. S., Mett I. L.,
Rebrikov, D., Brodianski, V. M., Kemper, O. C., Kollet, O., Lapidot, T. S., Soffer, D., Sobe T.,
Avraham, K. B., Goncharov, T., Holtmann, H., Lonai, P. and Wallach, D. (1998). Targeted disruption of
the mouse caspase-8 gene ablates cell-death induction by the TNF receptors, Fas/Apo1, and DR3 and is
lethal prenatally. Immunity, 9, 267-276.
115. Carpentier I, Declercq W, Malinin NL, Wallach D, Fiers W, Beyaert R (1998) TRAF2 plays a dual role
in NF-kappaB-dependent gene activation by mediating the TNF-induced activation of p38 MAPK and
IkappaB kinase pathways. FEBS Lett., 425,195-198.
116. Akiba H, Nakano H, Nishinaka S, Shindo M, Kobata T, Atsuta M, Morimoto C, Ware CF, Malinin NL,
Wallach D, Yagita H, Okumura K (1998) CD27, a member of the tumor necrosis factor receptor
superfamily, activates NF-kappaB and stress-activated protein kinase/c-Jun N-terminal kinase via
TRAF2, TRAF5, and NF-kappaB-inducing kinase. J Biol Chem., 273,13353-13358.
117. Sylla BS, Hung SC, Davidson DM, Hatzivassiliou E, Malinin NL, Wallach D, Gilmore TD, Kieff E,
Mosialos G (1998) Epstein-Barr virus-transforming protein latent infection membrane protein 1 activates
transcription factor NF-kappaB through a pathway that includes the NF-kappaB-inducing kinase and the
IkappaB kinases IKKalpha and IKKbeta. Proc Natl Acad Sci U S A. 95, 10106-10111.
118. Li Y, Kang J, Friedman J, Tarassishin L, Ye J, Kovalenko A, Wallach D, Horwitz MS (1999)
Identification of a cell protein (FIP-3) as a modulator of NF-kappaB activity and as a target of an
adenovirus inhibitor of tumor necrosis factor alpha-induced apoptosis Proc Natl Acad Sci U S A
96,1042-1047
119. Watts AD, Hunt NH, Wanigasekara Y, Bloomfield G, Wallach D, Roufogalis BD and Chaudhri G
(1999) A casein kinase I motif present in the cytoplasmic domain of members of the tumour necrosis
factor ligand family is implicated in 'reverse signalling'. EMBO J 118, 2119-2126.
120. Holtmann H, Winzen R, Holland P, Eickemeier S, Hoffmann E, Wallach D, Malinin NL, Cooper JA,
Resch K, Kracht M. (1999) Induction of interleukin-8 synthesis integrates effects on transcription and
mRNA degradation from at least three different cytokine- or stress-activated signal transduction
pathways. Mol Cell Biol. 19, :6742-53.
121. Zhang S. Q, Kovalenko A., Cantarella G. and Wallach, D. (2000) Recruitment of the I-kappa-B-kinase
(IKK) signalosome to the p55 TNF receptor: RIP and A20 bind to NEMO (IKK) upon receptor
stimulation. Immunity. 12, 301-313.
122. Eliaz RE, Wallach D, Kost J. (2000) Delivery of soluble tumor necrosis factor receptor from in-situ
forming PLGA implants: in-vivo. Pharm Res. 2000 17, 1546-50.
123. Wallach D., Arumugam TU, Boldin MP, Cantarella G, Ganesh KA, Goltsev Y, Goncharov TM,
Kovalenko AV, Rajput A, Varfolomeev EE and Zhang SQ (2002) How are the regulators regulated? The
search for mechanisms that impose specificity on induction of cell death and NF-B activation by
members of the TNF/NGF receptor family. Arthritis Res. 4 (suppl 3), S189-S196.
124. Heussler VT, Rottenberg S, Schwab R, Kuenzi P, Fernandez PC, McKellar S, Shiels B, Chen ZJ, Orth
K, Wallach D and Dobbelaere DA. (2003) Hijacking of host cell IKK signalosomes by the transforming
parasite Theileria. Science. 298, 1033-6.
125. Schuchmann M, Varfolomeev EE, Hermann F, Rueckert F, Strand D, Koehler H, Strand S, Lohse AW,
Wallach D and Galle PR (2003). Dominant negative MORT1/FADD rescues mice from CD95 and TNFinduced liver failure. Hepatology 37, 129-135.
126. Kovalenko A, Chable-Bessia C, Cantarella G, Israël A, Wallach D and Courtois G. (2003) Tumor
suppressor CYLD negatively regulates NF-B signaling by deubiquitynation. Nature 424, 801-805.
127. Zalcenstein A, Stambolsky P, Weisz L, Muller M, Wallach D, Goncharov TM, Krammer PH, Rotter V
and Oren M. (2003) Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by
tumor-associated p53 mutants. Oncogene 22, 5667-5676.
128. Engelmann H, Aderka D and Wallach D. (2004) Purification of TNF Binding Proteins. Methods Mol
Med. 98, 23-32.
129. Greenberger S, Shaish A, Varda-Bloom N, Levanon K, Breitbart E, Goldberg I, Barshack I, Hodish I,
Yaacov N, Bangio L, Goncharov T, Wallach D and Harats D. (2004) Transcription-controlled gene
therapy against tumor angiogenesis. J Clin Invest. 113, 1017-1024.
130. Kang T-B, Ben-Moshe T, Varfolomeev E E, Pewzner-Jung Y, Yogev N, Jurewicz A, Waisman A,
Brenner O, Haffner R, Gustafsson E, Ramakrishnan P, Lapidot T and Wallach D (2004) Caspase-8 serves
both apoptotic and non-apoptotic roles. J Immunol. 173, 2976–2984.
131. Xanthoulea S, Pasparakis M, Kousteni S, Brakebusch C, Wallach D, Bauer J, Lassmann H and Kollias
G (2004) Tumor necrosis factor (TNF) receptor shedding controls thresholds of innate immune activation
that balance opposing TNF functions in infectious and inflammatory diseases. J Exp Med. 200, 367-376.
132. Ramakrishnan P, Wang W, and Wallach D. (2004) Receptor-specific signaling for both the alternative
and the canonical NF-B activation pathways by NF-B-inducing kinase (NIK). Immunity 21, 477-489.
133. Schuchmann M, Ruckert F, Garcia-Lazaro JF, Karg A, Burg J, Knorr N, Siebler J, Varfolomeev EE,
Wallach D, Schreiber W, Lohse AW and Galle PR. (2005) MORT1/FADD is involved in liver
regeneration. World J Gastroenterol. 11, 7248-53.
134. Citri, A., Harari, D., Shohat, G, Ramakrishnan, P, Gan, J,, Lavi, S,, Eisenstein, M,, Kimchi, A,
,Wallach, D., Pietrokovski, S, and Yarden, Y. (2006) Hsp90 recognizes a common surface on client
kinases. J Biol Chem. 281, 14361-14369.
135. Sanchez-Valdepenas, C,, Martin, AG,, Ramakrishnan, P, Wallach, D, and Fresno M. (2006) NFkappaB-inducing kinase is involved in the activation of the CD28 responsive element through
phosphorylation of c-Rel and regulation of its transactivating activity. J Immunol. 176, 4666-7674.
136. Helfer B, Boswell BC, Finlay D, Cipres A, Vuori K, Bong Kang T, Wallach D, Dorfleutner A, Lahti
JM, Flynn DC, and Frisch SM. (2006) Caspase-8 promotes cell motility and calpain activity under
nonapoptotic conditions. Cancer Res. 66, 4273-4278.
137. Gyrd-Hansen, M., Farkas, T., Fehrenbacher, N., Bastholm, L., Høyer-Hansen, M., Elling, F., Wallach,
D., Flavell, R., Kroemer, G., Nylandsted, J, and Jäättelä, M. (2006) Apoptosome-independent activation
of the lysosomal cell death pathway by caspase-9. Mol. Cell. Biol. 26, 7880-7801.
138. Ben Moshe, T., Barash, H., Kang, T-B., Kim, J-C., Kovalenko, A., Gross, E., Schuchmann, M.,
Abramovitch, R., Galun, E. and Wallach, D., (2007) Role of Caspase-8 in Hepatocyte Response to
Infection and Injury in Mice. Hepatology 45, 1014-1024.
139. Hövelmeyer, N., Wunderlich, T. F, Massoumi, R., Jakobsen, C, G., Song, J., Wörns, M. A.,
Merkwirth, C., Kovalenko, A., Aumailley, M., Strand, D., Brüning, J. C., Galle, P. R., Wallach, D.,
Fässler, R., and Waisman, A. (2007) Regulation of B cell homeostasis and activation by the tumor
suppressor gene Cyld. J. Exp. Med. 204, 2615-2627.
140. Ben Moshe, T., Kang, T-B., Kovalenko, A., Barash, H., Abramovitch, R., Galun, E. and Wallach, D.
(2008) Cell-autonomous and non-cell-autonomous functions of caspase-8. Cytokine Growth Factor Rev.
19, 209-17.
141. Krelin, Y., Zhang, L., Kang, T-B., Appel, E., Kovalenko, A. and Wallach, D. (2008) Caspase-8
deficiency facilitates cellular transformation in vitro. Cell Death Differ. 15, 1350-1355.
142. Kang, T-B., Oh, G-S., Scandella, E., Bolinger, B., Ludewig, B., Kovalenko, A. and Wallach, D. (2008)
Mutation of a self-processing site in caspase-8 compromises its apoptotic but not its nonapoptotic
functions in bacterial artificial chromosome-transgenic mice. J Immunol. 181, 2522-2532.
143. Scharner, D., Rössig, L., Carmona, G., Chavakis, E., Urbich, C., Fischer, A., Kang, T-B., Wallach, D.,
Chiang, Y. J., Deribe, Y. L., Dikic, I., Zeiher, A. M. and Dimmeler, S. (2009) Caspase-8 is involved in
neovascularization-promoting progenitor cell functions. Arterioscler Thromb Vasc Biol. 29, 571-578.
144 Kovalenko, A., Kim J-C., Kang, T-B., Rajput, A., Bogdanov, K., Dittrich-Breiholz, O., Kracht, M.,
Brenner, O., and Wallach, D. (2009) Caspase-8 deficiency in epidermal keratinocytes triggers an
inflammatory skin disease J. Exp. Med. 206, 2161-2177.
145. Rajput, A., Kovalenko, A., Bogdanov, K., Yang, S-H., Kang, T-B., Kim, J-C., Jianfang Du, J and
Wallach, D. (2011) RIG-I RNA Helicase Activation of IRF3 Transcription Factor is Negatively
Regulated by Caspase-8-Mediated Cleavage of the RIP1 protein. Immunity 34, 1-12.
146. Dillon, C. P., Obserst, A., Weinlich, R., Janke, L. J., Kang, T. B., Ben-Moshe, T., Mak, T. W., Wallach,
D. and Green, D. R. (2012) Survival function of the FADD-CASPASE-8-cFLIP(L) complex. Cell Rep.
1, 401-407.
147. Kang, T-B., Yang, S-H., Toth, B., Kovalenko, A., and Wallach, D. (2012) Caspase-8 withholds kinase
RIPK3-mediated activation of the NLRP3 inflammasome. Immunity (in press)
Reviews, Proceedings of Conferences and Chapters in Books
1b. Wallach, D., Davies, P., Bechtel, P., Willingham, M. and Pastan, I. (1978): Cyclic AMP dependent
phosphorylation of the actin binding protein filamin: Advances in Cyclic Nucleotide Research, Vol. 9,
Raven Press (New York) pp. 371-379 (W.J. George and L.J. Ignarro, eds.).
2b. Wallach, D. and Revel, M. (1981): Cell-virus interaction and interferon. In: Struc-tural Aspects of
Recognition and Assembly in Biological Macromolecules. 7th Aharon Katzir-Katchalsky Conference,
Rehovot, Israel. (Balaban, M., J.L. Sussman, W. Traub and A. Yonath, eds.) Balaban, ISS, (Rehovot
and Philadelphia) pp. 937-948.
3b. Revel, M., Wallach, D., Merlin, G., Schattner, A., Schmidt, A., Wolf, D., Shulman, L. and Kimchi, A.
(1981): Interferon-induced enzymes: microassays and their applications. In: Methods in Enzymology,
Vol. 79, Interferon Part B, New York Academic Press, ed. Pestka, S., pp. 149-161.
4b.Wallach, D., Schattner, A., Merlin, G., Kimchi, A., Fellous, M. and Revel, M. (1982): Interferon-induced
proteins: Biological Functions and Clinical Applications. In: Chemistry and Biology of Interferons:
Relationship to Therapeutics, UCLA Sym-posium on Molecular and Cellular Biology, Vol. XXV
(Thomas C. Merigan, Robert M. Friedman and Fred C. Fox, eds.). Academic Press, 1982, pp. 449-463.
5b. Revel, M., Schattner, A., Wallach, D., Merlin, G., Levavi, H., Hahn, T. and Levin, S. (1982): Monitoring
of interferon-therapy, diagnosis of viral diseases and detection of interferon-deficiencies by assay of an
interferon-induced enzyme in human peripheral white blood cells. In: Clinical Potentials of Interferon in
Viral Diseases and Malignant Tumors . (R. Kono, ed.) Tokyo University Press, pp. 353-367.
6b.Wallach, D. (1982): The secretory granule of the parotid gland. In: The Secretory Granule.
Elsevier/North Holland Press. (A. Poisner and J. Trifaro, eds.) pp. 247-276.
7b.Wallach, D. (1982): Resistance to natural killer cells cytotoxicity and HLA synthesis: differing regulatory
efficiency of the Type I and immune interferons. In: Human Lymphokines, The Biological Immune
Response Modifiers (Khan, A. and Hill, N.O., eds.). Academic Press, pp. 435-449.
8b.Wallach, D., Aderka, D., Budilovsky, S. and Hahn, T. (1983): Interferon enhances the production of
lymphotoxins and potentiates their cytotoxic effect. In: The Biology of the Interferon System 1983 (E.
de Maeyer and H. Schellekens, eds.) Elsevier/Science Publishers, pp. 293-303.
9b.Wallach, D. (1986): Cytotoxins (tumor necrosis factor, lymphotoxin and others): Molecular and
functional characteristics and interactions with interferons. In: Interferon 7 (Ion Gresser, ed.). Academic
Press (London), 89-122.
10b.Wallach, D., Holtmann, H., Hahn, T. and Israel, S. (1986): Interactions of tumor necrosis factor,
interferon and interleukin-1 in cell killing In: The Biology of the Interferon System. 1986. (K. Cantell
and H. Schellekens, eds.) Martinus Nijhoff Publishers (Dordrecht) 223-230.
11b.Wallach, D., Cantell, K., Hirvonen, S., Toker, L., Aderka, D. and Holtmann, D. (1986). Presence of
tumor necrosis factor and lymphotoxin in clinical interferon preparations derived from leukocytes. In:
The Biology of the Interferon System. 1986. (K. Cantell and H. Schellekens, eds.) Martinus Nijhoff
Publishers (Dordrecht) 251-256.
12b.Wallach, D. (1987). Protective and cytolytic effects of TNF. In: Tumor Necrosis Factor and Related
Cytotoxins. CIBA Found. Symp. 131. J. Wiley & Sons (Chichester) 84-86.
13b.Wallach, D., Nophar, Y., Aderka, D., Israel, S., Hahn, T., Engelmann, H., Holtmann, H. (1988).
Regulation of the response to tumor necrosis factor. In: Tumor Necrosis Factor, Lymphotoxins, and
Related Cytokines. (H. Kirchner, B. Bonavida and L. Old, eds.) S. Karger Verlag (Basel) 134-147.
14b.Wallach, D., Holtmann, H., Aderka, D., Hahn, T., Engelmann, H. and Nophar, Y. (1988). Sensitizing
effects and mechanisms of desensitization in regulation of the in vivo response to TNF. In: The Multiple
Roles of Tumor Necrosis Factor. 22e Forum D'Immunologie. Ann. Inst. Pasteur/Immunol. 139.
Elsevier (Paris) 323-327.
15b. Wallach, D., Aderka, D., Rubinstein, M., Engelmann, H., Shemer Avni, Y., Sarov, I. and Holtmann, H.
(1989). Mechanisms involved in regulation of the response to tumor necrosis factor. Possible roles for
prostaglandin production in sensitization to TNF effects and for a specific TNF-binding protein in
protection from them. In: Tumor Necrosis Factor II (B. Bonavida and G. Granger, eds.). S. Karger,
Verlag (Basel), 146-155.
16b Engelmann, H., Aderka, D., Holtmann, H., Brakebusch, C. Nophar, Y., Novick, D., Kemper, O.,
Rubinstein, M., Shemer-Avni, Y., Sarov, I. and Wallach, D. (1990): Soluble forms of the TNF receptors,
purified from human urine, inhibit TNF effects. Antibodies against the soluble receptors induce TNFlike effects. In: Molecular and Cellular Biology of Cytokines (J.J. Oppenheim, M.C. Powanda, M.J.
Kluger and C.A. Dinarello, eds.) Alan R. Liss (New York), 299-308.
17b. Novick, D., Engelmann, H., Wallach, D. and Rubinstein, M. (1990): Soluble cytokine receptors are
present in normal urine. In: The Physiological and Pathological effects of Cytokines (C.A. Dinarello,
M.J. Kluger, M.C. Powanda and J.J. Oppenheim, eds.) Alan R. Liss (New York) 413-421.
18b. Shemer-Avni, Y., Holtmann, H., Wallach, D. and Sarov, I. (1990): Cytokine-cell interactions resulting
in chlamydia trachomatis inhibition-mechanisms involved. In: Chlamydial infections. Proceeding of the
7th International Symposium on human chlamydial infection, Vancouver (J. Schachter, ed.) Cambridge
Univ. Press. In press.
19b.Wallach, D., Aderka, D., Engelmann, H., Nophar, Y., Kemper, O., Holtmann, H., Villa, S., Bucciarelli,
U. and Brakebusch, C. (1991). Cell-surface and soluble TNF-receptors. In: Tumor Necrosis-Factor III
(T. Osawa and B. Bonavida, eds.) S. Karger, Verlag (Basel), 47-57.
20b. Holtmann, H., Brakebusch, C., König, M., Klocke, R., Winzen, R., Resch, K. and Wallach, D. (1991):
Mechanisms controlling the level of receptors for tumor necrosis factor. In: Agents and Actions 32.
Birkhäuser Verlag, Basel, 106-108.
21b. Wallach, D., Engelmann, H., Nophar, Y., Aderka, D., Kemper, O., Hornik, V., Holtmann, H., and
Brakebusch, C. (1991): Soluble and cell surface receptors for tumor necrosis factor. In: Agents Actions
Suppl (Switzerland), Progress in Inflammation, Research and Therapy. Birkhäuser Verlag, Basel, 51-57.
22b. Engelmann, H., Aderka, D., Novik, D., and Wallach, D (1993): Löslische Zytokinreceptoren Transport proteine oder endogene Zytokininhibitoren. (1993) In: Zytokine. 22. Symposium der
Gesellschaft für Fortschritte in der Inneren Medizine, Köln (Wolfgang Wilmanns ed.) Georg Thieme
Verlag (Stuttgart. New York), 20-26.
23b.Brakebusch. C., Nophar, Y., Kemper, O., Aderka, D., Engelmann, H. and Wallach, D. (1993): Diverse
functions of the tumor necrosis factor receptors: structure-activity considerations. In: Tumor NecrosisFactor IV (W. Fiers ed.) S. Karger, Verlag (Basel), 40-51.
24b. Aderka, D., Engelmann, H., and Wallach, D. (1993): Soluble Tumor Necrosis Factor Receptors in
Health and Disease. In: Tumor Necrosis-Factor IV (W. Fiers and W. A. Buurman eds.) S. Karger,
Verlag (Basel), 191-198.
25b Wallach, D. (1993) The term "Cytokines". In: Encyclopaedia Hebraica (D. Shacham ed.) Encyclopaedia
Publishing Company (Jerusalem), in press.
26b Wallach, D., Bigda, Y., Brakebusch, C., Beletsky, I., Aderka, D., Holtmann, H., Engelmann, H., Hornik,
V., Shemer, Y., Mett, I. and Kemper, O. (1994) Variations in effectvity of mechanisms which restrict the
cellular response to TNF. In: Challenges of modern medicine, Volume 3: Molecular basis of
inflammation (J. Navarro ed.) Ares-Serono Symposia Publications (Rome), 169-178.
27b Feinstein, E., Wallach, D., Boldin, M., Varfolomeev, E. and Kimchi, A. (1995) The death domain: a
module shared by proteins with diverse cellular functions. TIBS, 29, 342-344.
28b. Wallach, D. (1996) A decade of accumulated knowledge and emerging answers. The sixth international
congress on TNF. Eur. Cytokine Net. 7, 713-724.
29b. Wallach, D., Boldin, M. Goncharov, T., Goltsev, Y., Mett, I., Malinin, N., Adar, R., Kovalenko, A. and
Varfolomeev, E. (1996) Exploring cell death mechanisms by analyzing signaling cascades of the
TNF/NGF receptor family. In: Behring Inst. Mitt., No. 97, 144-155.
30b. Wallach, D. (1996) Suicide by order: some open questions about the cell-killing activities of the TNF
ligand and receptor families. In: Cytokine & Growth factor reviews, 7, 211-221.
31b. Wallach, D. (1997) Cell death induction by TNF: a matter of self control. Trends Biochem. Sci., 22,
107-109.
32b. Wallach, D. (1997) Cytokine receptors, soluble. In: Encyclopedia of Immunology (2nd Edn) 712-719.
33b. Wallach, D. (1997) TNF receptors. In: Encyclopedia of Immunology (2nd Edn), 2345-2349
34b. Wallach, D., Boldin, M., Varfolomeev, E., Beyaert, R., Vandenabeele, P., Fiers, W. (1997) Cell death
induction by receptors of the TNF family: towards a molecular understanding. FEBS Lett. 410, 96 -106.
35.b. Wallach, D. (1997) Placing death under control. Nature,388 ,123-127.
36b.Wallach, D. , Boldin, M. P., Kovalenko, A. V., Malinin, N. L., Mett, I. L. and Camonis J. H. (1998) The
yeast two-hybrid screening technique and its use in the study of protein-protein interactions in apoptosis.
Current Opinion in Immunology 10, 131-136.
37b. Wallach, D. , Kovalenko, A. V., Varfolomeev, E. E. and Boldin, M. P. (1998) Death-inducing functions
of ligands of the TNF family: a Sanhedrin verdict. Current Opinion in Immunology 10, 279-288.
38b. Wallach, D., Bigda, J and Engelmann, H. (1999) The TNF family and related molecules. In: The
cytokine network and immune functions (J. Thèze ed.) Oxford University Press, (Oxford), 51-84.
39b. Wallach, D., Varfolomeev, E. E., Malinin, N. L., Goltsev, Y. V., Kovalenko A. V. and Boldin, M. P
(1999) TNF receptor and Fas signaling mechanisms. Ann Rev Immunol. 17, 331-367.
40b. Wallach, D. (2000) TNF ligand and TNF/NGF receptor families. In: Cytokine Reference (Joost J.
Oppenheim and Marc Feldmann editors in chief). Academic Press (London), 1565 – 1586.
http://www.apnet.com/cytokinereference/
41b. Wallach D. (2002) Up the down staircase. Nat Immunol. 3, 984.
42b. Wallach D. (2005) Probing cell death by chemical screening . Nat Chem. Biol. 1, 68-69.
43b. Kovalenko, A. and Wallach, D. (2006) If the prophet does not come to the mountain: dynamics of
signaling complexes in NF-kappaB activation. Mol Cell. 22, 433-436.
44b. Peter, ME., Budd, R. C., Desbarats, J., Hedrick, S. M., Hueber, A. O., Newell, M. K., Owen, L. B.,
Pope, R. M., Tschopp, J., Wajant, H., Wallach. D., Wiltrout, R. H., Zornig, M. and Lynch DH. (2007)
The CD95 receptor: apoptosis revisited. Cell. 129, 447-450.
45b. Wallach, D., Kang, T-B. and Kovalenko, A. (2008) The extrinsic cell death pathway and the élan
mortel. Cell Death Differ 15, 1533-1541.
46b. Wallach, D. and Kovalenko, A. (2008) Self-termination of the terminator. Nat Immunol. 9, 1525-7
47b. Wallach, D. and Kovalenko, A. (2009) 12th international TNF conference: the good, the bad and the
scientists. Cell Death Differ 20, 259-269.
48b. Wallach, D., Kang, T-B., Rajput, R., Kim, J-C., Bogdanov, K., Yang, S-H. and Kovalenko, A (2010)
Anti-inflammatory functions of the ‘apoptotic’ caspases. Ann N. Y. Acad. Sci. 1209, 17-22.
49b. Wallach, D., Kovalenko, A. and Feldmann, M. (eds) (2011) Advances in TNF Family Research:
Proceedings of the 12th International TNF Conference, 2009. (Advances In Experimental Medicine And
Biology, Vol. 691). Springer. New York, 1-844.
50b. Rajput, A., Kang., T-B, Bogdanov, K., Kim, J-C., Ben-Moshe, T., Kovalenko, A. and Wallach, D.
(2011) Anti-inflammatory functions of caspase-8. Adv Exp Med Biol. 691:253-60.
51b. Wallach, D. (2011) In Memoriam. Jürg Tschopp. Cytokine 54: 233-234.
52b. Wallach, D., Kovalenko, A. and Kang, T-B. (2011) ‘Necrosome’-induced inflammation: must cells die
for it? Trends in Immunology 32:505-509.